We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+13.94%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$518M
AUM Growth
+$159M
Cap. Flow
+$131M
Cap. Flow %
25.19%
Top 10 Hldgs %
65.06%
Holding
140
New
98
Increased
11
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
NCDL icon
Nuveen Churchill Direct Lending
NCDL
+$70.6M
2
TQQQ icon
ProShares UltraPro QQQ
TQQQ
+$22.3M
3
CNDT icon
Conduent
CNDT
+$12.3M
4
HLLY icon
Holley
HLLY
+$8.52M
5
GAQ
Generation Asia I Acquisition Limited Class A Ordinary Shares
GAQ
+$5.23M

Top Sells

Rank Stock Value
1
TOST icon
Toast
TOST
+$8.31M
2
VKTX icon
Viking Therapeutics
VKTX
+$5.57M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$5.35M
4
TRML
Tourmaline Bio
TRML
+$3.09M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$3.08M

Sector Composition

Rank Sector Weight
1 Healthcare 53.22%
2 Financials 20.04%
3 Technology 17.47%
4 Consumer Discretionary 1.45%
5 Industrials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMT icon
26
Sagimet Biosciences
SGMT
$559M
$4.64M 0.89%
1,673,877
– –
STWD icon
27
Starwood Property Trust
STWD
$6.09B
$4.62M 0.89%
226,456
– –
PYXS icon
28
Pyxis Oncology
PYXS
$236M
$4.13M 0.8%
1,126,025
+80,000
+8% +$280K
CNTA
29
DELISTED
Centessa Pharmaceuticals
CNTA
$4.08M 0.79%
+255,000
New +$3.12M
JANX icon
30
Janux Therapeutics
JANX
$967M
$3.63M 0.7%
80,000
+40,000
+100% +$1.74M
AEON icon
31
AEON Biopharma
AEON
$13.5M
$3.51M 0.68%
+46,406
New +$4.08M
MREO
32
Mereo BioPharma
MREO
$47.3M
$3.48M 0.67%
847,809
-50,000
-6% -$207K
GPCR icon
33
Structure Therapeutics
GPCR
$3.78B
$2.85M 0.55%
65,000
+10,000
+18% +$387K
VKTX icon
34
CALL
Viking Therapeutics
VKTX
$4B
$2.6M 0.5%
+41,000
New +$2.41M
BRZE icon
35
Braze
BRZE
$2.99B
$2.53M 0.49%
+78,222
New +$3.09M
MLYS icon
36
Mineralys Therapeutics
MLYS
$2.41B
$2.38M 0.46%
196,132
-254,207
-56% -$3.08M
ADCT icon
37
ADC Therapeutics
ADCT
$144M
$2.31M 0.45%
733,568
– –
IMVT icon
38
Immunovant
IMVT
$8.25B
$2.28M 0.44%
80,000
– –
BLND icon
39
Blend Labs
BLND
$386M
$1.36M 0.26%
361,587
– –
PAYO icon
40
Payoneer
PAYO
$2.41B
$1.33M 0.26%
+208,203
New +$1.35M
OMGA
41
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$1.29M 0.25%
1,055,882
– –
NU icon
42
Nu Holdings
NU
$66.9B
$1.25M 0.24%
+91,324
New +$1.23M
SYRS
43
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.11M 0.21%
515,855
+175,000
+51% +$629K
EPD icon
44
Enterprise Products Partners
EPD
$81.7B
$911K 0.18%
+31,290
New +$914K
SHFS icon
45
SHF Holdings
SHFS
$1.13M
$835K 0.16%
+75,896
New +$920K
GOCO
46
DELISTED
GoHealth
GOCO
$781K 0.15%
83,264
– –
UVXY icon
47
ProShares Ultra VIX Short-Term Futures ETF
UVXY
$293M
$748K 0.14%
+6,000
New +$782K
ENGNW icon
48
enGene Therapeutics Warrants
ENGNW
$728K 0.14%
511,177
+460,000
+899% +$543K
GATE
49
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
$687K 0.13%
+91,429
New +$1.01M
ROIV icon
50
Roivant Sciences
ROIV
$26.2B
$450K 0.09%
+39,003
New +$444K
1
2
3 4 5

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
JC
Joho Capital New York $373M AUM 18.89% 1-Year Est. Return

Blue Owl Capital Holdings's Q3 2024 Portfolio in Review

As of Q3 2024, Blue Owl Capital Holdings held 140 positions worth $518M, up 44% from $360M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Blue Owl Capital Holdings deployed $131M of net new capital in Q3 2024, opening 98 new positions and adding to 11 existing holdings. Its largest new stake was Nuveen Churchill Direct Lending: 4,039,553 shares worth $70.4M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 72% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Ultragenyx Pharmaceutical, an estimated $5.35M trimmed.

  • Blue Owl Capital Holdings's largest Q3 2024 buy was Nuveen Churchill Direct Lending: 4,039,553 shares worth $70.4M.
  • Blue Owl Capital Holdings added most to enGene Therapeutics in Q3 2024, an estimated $4.53M increase.
  • Blue Owl Capital Holdings's biggest Q3 2024 reduction was Ultragenyx Pharmaceutical, cutting an estimated $5.35M.
  • Blue Owl Capital Holdings fully exited Toast in Q3 2024, selling an estimated $8.31M.
  • Blue Owl Capital Holdings's ten largest holdings make up 65% of its $518M portfolio in Q3 2024.
  • Blue Owl Capital Holdings opened 98 new positions and closed 3 in Q3 2024.
  • Blue Owl Capital Holdings's portfolio value rose 44% quarter-over-quarter to $518M.

Based on Blue Owl Capital Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.